BRPI0518777A2 - usos de um agonista do receptor de adenosina a3 (a3ar) e de metotrexato (mtx) - Google Patents

usos de um agonista do receptor de adenosina a3 (a3ar) e de metotrexato (mtx)

Info

Publication number
BRPI0518777A2
BRPI0518777A2 BRPI0518777-0A BRPI0518777A BRPI0518777A2 BR PI0518777 A2 BRPI0518777 A2 BR PI0518777A2 BR PI0518777 A BRPI0518777 A BR PI0518777A BR PI0518777 A2 BRPI0518777 A2 BR PI0518777A2
Authority
BR
Brazil
Prior art keywords
a3ar
inflammatory state
subject
level
wbc
Prior art date
Application number
BRPI0518777-0A
Other languages
English (en)
Inventor
Pnina Fishman
Sara Bar-Yehuda
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518777(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of BRPI0518777A2 publication Critical patent/BRPI0518777A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rehabilitation Therapy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

USOS DE UM AGONISTA DO RECEPTOR DE ADENOSINA A3 (A3AR) E DE METOTREXATO (MTX). A presente invenção diz respeito ao tratamento terapêutico de condições inflamatórias por uma administração combinada de metotrexato e um agonista do receptor de adenosina A3. São fornecidos métodos de tratamento terapêutico que compreende uma tal administração combinada, composições farmacêuticas úteis em tais métodos que compreende o uso de um agonista do receptor de adenosina A3 ou metotrexato, bem como o uso de qualquer um destes agentes ativos para a preparação de uma tal composição farmacêutica.
BRPI0518777-0A 2004-12-02 2005-11-30 usos de um agonista do receptor de adenosina a3 (a3ar) e de metotrexato (mtx) BRPI0518777A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63219804P 2004-12-02 2004-12-02
US65771805P 2005-03-03 2005-03-03
PCT/IL2005/001280 WO2006059328A1 (en) 2004-12-02 2005-11-30 Treatment of inflammation

Publications (1)

Publication Number Publication Date
BRPI0518777A2 true BRPI0518777A2 (pt) 2008-12-09

Family

ID=35708899

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0518795-8A BRPI0518795A2 (pt) 2004-12-02 2005-11-30 mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio
BRPI0518777-0A BRPI0518777A2 (pt) 2004-12-02 2005-11-30 usos de um agonista do receptor de adenosina a3 (a3ar) e de metotrexato (mtx)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0518795-8A BRPI0518795A2 (pt) 2004-12-02 2005-11-30 mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio

Country Status (13)

Country Link
US (3) US20080056992A1 (pt)
EP (2) EP1817589B1 (pt)
JP (2) JP4842964B2 (pt)
KR (2) KR20070100261A (pt)
AT (2) ATE402739T1 (pt)
AU (2) AU2005310874B2 (pt)
BR (2) BRPI0518795A2 (pt)
CA (2) CA2586773C (pt)
DE (2) DE602005015135D1 (pt)
DK (1) DK1817079T3 (pt)
ES (2) ES2309817T3 (pt)
MX (2) MX2007006500A (pt)
WO (2) WO2006059328A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043054A1 (en) * 2005-10-12 2007-04-19 Can-Fite Biopharma Ltd. Treatment and monitoring disease state of liver cancer
JP5339916B2 (ja) * 2005-11-30 2013-11-13 キャン−ファイト・バイオファーマ・リミテッド 骨関節炎の治療におけるａ３アデノシン受容体アゴニストの使用
US20080183101A1 (en) * 2006-08-17 2008-07-31 Jonathan Richard Stonehouse Salivary analysis
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008056361A1 (en) * 2006-11-09 2008-05-15 Can-Fite Biopharma Ltd. A biological marker for psoriasis
PT2137202T (pt) 2007-03-14 2017-10-02 Can-Fite Biopharma Ltd Processo para a síntese de ib-meca
IL200753A (en) * 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
US20130045943A1 (en) * 2010-03-03 2013-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of A3ar agonists for the treatment of uveitis
US20130165399A1 (en) 2010-06-18 2013-06-27 Hayashibara Co., Ltd. Therapeutic agent for inflammatory diseases, containing adenosine n1-oxide as an effective ingredient
KR102095284B1 (ko) 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61502124A (ja) 1984-05-09 1986-09-25 ジ　オ−ストラリアン　ナシヨナル　ユニヴア−シテイ− 免疫応答の調節方法
AU5182500A (en) 1996-08-01 2000-10-26 Kennedy Institute Of Rheumatology, The Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
ATE247974T1 (de) 1996-12-06 2003-09-15 Amgen Inc Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US20020179549A1 (en) * 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
JP2004135657A (ja) * 2002-08-21 2004-05-13 Kyowa Hakko Kogyo Co Ltd ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物
JP2006503564A (ja) * 2002-10-21 2006-02-02 カン−フィテ・バイオファーマ・リミテッド 治療学的処置のための診断マーカー
US20040229246A1 (en) * 2002-10-21 2004-11-18 Can-Fite Biopharam Ltd. Diagnostic markers for therapeutic treatment
US20040137477A1 (en) * 2002-10-22 2004-07-15 Can-Fite Biopharma, Ltd. A3AR as a marker for a diseased state
AU2003282359A1 (en) * 2002-11-19 2004-06-15 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
US20050074451A1 (en) 2003-06-25 2005-04-07 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
EP1699459B1 (en) 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Method for treatment of multiple sclerosis

Also Published As

Publication number Publication date
ES2309817T3 (es) 2008-12-16
MX2007006500A (es) 2007-07-13
JP4842964B2 (ja) 2011-12-21
JP2008522182A (ja) 2008-06-26
JP2008521883A (ja) 2008-06-26
US8541182B2 (en) 2013-09-24
ATE434762T1 (de) 2009-07-15
DE602005008639D1 (de) 2008-09-11
US20130345163A1 (en) 2013-12-26
KR20070090222A (ko) 2007-09-05
DK1817079T3 (da) 2008-11-17
US20100256084A1 (en) 2010-10-07
DE602005015135D1 (de) 2009-08-06
KR20070100261A (ko) 2007-10-10
AU2005310874B2 (en) 2008-11-27
EP1817079A1 (en) 2007-08-15
CA2586774A1 (en) 2006-06-08
AU2005310873A1 (en) 2006-06-08
CA2586773C (en) 2018-03-27
CA2586773A1 (en) 2006-06-08
EP1817589B1 (en) 2009-06-24
BRPI0518795A2 (pt) 2008-12-09
WO2006059327A1 (en) 2006-06-08
ES2327435T3 (es) 2009-10-29
AU2005310873B2 (en) 2008-11-27
WO2006059328A1 (en) 2006-06-08
AU2005310874A1 (en) 2006-06-08
MX2007006501A (es) 2007-07-13
ATE402739T1 (de) 2008-08-15
EP1817079B1 (en) 2008-07-30
EP1817589A1 (en) 2007-08-15
US20080056992A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
WO2007123976A3 (en) Antibody profiling for determination of patient responsiveness
Cameron et al. Catch‐up growth or regression to the mean? Recovery from stunting revisited
ES2507549T3 (es) Detector móvil de señales de salud y de vida
DK1817079T3 (da) Behandling af inflammationer
WO2008041953A3 (en) Dengue diagnosis and treatment
WO2009025847A3 (en) Methods for diagnosis, prognosis and methods of treatment
BR112012015669B1 (pt) Ciclizador de diálise peritoneal automático e métodos de uso
EP1447665A3 (en) Method for reducing effect of hematocrit on measurement of an analyte in whole blood, and test kit and test article useful in the method
ATE530635T1 (de) Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status
MY158262A (en) Diagnosis and treatments of cancers and other conditions
Wray et al. Hepcidin detects iron deficiency in S ri L ankan adolescents with a high burden of hemoglobinopathy: A diagnostic test accuracy study
WO2005070086A3 (en) Methods and compositions for determining a graft tolerant phenotype in a subject
CY1111356T1 (el) Βελτιστοποιηση της θεραπειας της θετικης στο χρωμοσωμα της φιλαδελφειας λευχαιμιας με ιματινιμπη, εναν αναστολεα κινασης τυροσινης toy abl
Ustinova et al. Postural stabilization by gripping a stick with different force levels
Nduati et al. 2, 4-diaminopteridine-based compounds as precursors for de novo synthesis of antifolates: a novel class of antimalarials
TW200508936A (en) The establishment of proteome structure profile databases and their uses
FR2900936B1 (fr) Procede et methodes de detection de la maladie d'alzheimer
WO2004048550A3 (en) Immune response associated proteins
WO2003077875A3 (en) Proteins associated with growth, differentiation, and death
BR0209172A (pt) Método de detecção de doenças induzidas por glúten em uma amostra sanguìnea de um indivìduo, e kit teste para uso no método
WO2011113942A3 (en) Method for predicting the responsiveness to chemotherapy
WO2004031364A3 (en) Proteins associated with cell growth, differentiation, and death
Seither et al. Interconversion of tetrahydrofolate cofactors to dihydrofolate induced by trimetrexate after suppression of thymidylate synthase by fluorodeoxyuridine in L1210 leukemia cells
WO2003095622A8 (en) Proteins associated with cell growth, differentiation, and death
Barbour et al. Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.